1,247 results on '"Pratley, Richard E."'
Search Results
102. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
103. Introduction and Methodology: Standards of Care in Diabetes—2023
104. 7. Diabetes Technology: Standards of Care in Diabetes—2023
105. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
106. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
107. 6. Glycemic Targets: Standards of Care in Diabetes—2023
108. Erratum. 10. Cardiovascular disease and risk management: Standards of Care in Diabetes—2023. Diabetes Care 2023;46(Suppl. 1):S158–S190
109. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
110. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
111. Coordinated regulation of gene expression and microRNA changes in adipose tissue and circulating extracellular vesicles in response to pioglitazone treatment in humans with type 2 diabetes
112. Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
113. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
114. Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM)
115. Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial
116. Impact of a behaviorally-based weight loss intervention on parameters of insulin resistance in breast cancer survivors
117. Design and Rationale for the Use of Magnetic Resonance Imaging Biomarkers to Predict Diabetes Following Acute Pancreatitis in the Diabetes RElated to Acute Pancreatitis and Its Mechanisms (DREAM) Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)
118. Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)
119. GL0034, A novel long-acting glucagon-like peptide 1 receptor agonist exhibits significant efficacy in aged db/db mouse model of non-alcoholic fatty liver disease (NAFLD)
120. Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus
121. 592-P: Living with Type 1 Diabetes (T1DM) as an Older Adult: A Qualitative Study Examining Experiences and Attitudes about Continuous Glucose Monitoring (CGM)
122. 859-P: Effects of Ertugliflozin on Uric Acid and Gout-Related Outcomes: Post Hoc Analyses from VERTIS CV
123. 481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV
124. Closed-loop therapy in older adults with type 1 diabetes: hypoglycaemia benefits and risk stratification – Authors' reply
125. 744-P: Effects of a Novel Long-Acting GIP/GLP-1/Glucagon Trireceptor Agonist, HISHS-3001, on HbA1c, Body Weight, and Lipid Metabolism
126. 747-P: Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial
127. 865-P: Long-Term Ertugliflozin Treatment and Incidence of Hypoglycemia: Analyses from VERTIS CV
128. 559-P: The Advancing Care for T1D Obesity Network (ACT1ON) Sequential Multiple Assignment Randomized Trial Pilot Results for Effect on Weight and Glycemia
129. 737-P: Targeted Maximum Likelihood Estimation (TMLE) to Estimate the Effect of Liraglutide on Cardiovascular (CV) Outcomes in Race/Ethnicity Subgroups: Post Hoc Analysis of LEADER
130. Design of the Advancing Care for Type 1 Diabetes and Obesity Network energy metabolism and sequential multiple assignment randomized trial nutrition pilot studies: An integrated approach to develop weight management solutions for individuals with type 1 diabetes
131. 1281-P: Understanding the Interaction between Type 2 Diabetes and COVID-via Extracellular Vesicle Proteomic and Phosphoproteomic Signatures
132. 38-LB: Physical Activity and Glycemia among Young Adults with Type 1 Diabetes and Overweight or Obesity—Results from Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON)
133. 32-OR: The Advancing Care for T1D Obesity Network (ACT1ON) Sequential Multiple Assignment Randomized Trial Pilot Re-randomization Results
134. Proteomics and Phosphoproteomics of Circulating Extracellular Vesicles Provide New Insights into Diabetes Pathobiology
135. The Ile191Val Variant of the TAS1R2 Subunit of Sweet Taste Receptors Is Associated With Reduced HbA1c in a Human Cohort With Variable Levels of Glucose Homeostasis
136. The Early Treatment of Type 2 Diabetes
137. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
138. Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results.
139. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV
140. Correlates of circulating extracellular vesicle cargo with key clinical features of type 1 diabetes
141. Can technology improve the management of older adults with type 1 diabetes? Yes, but…
142. Indirect treatment comparisons: Choosing the right tool for the job
143. Author response for 'Indirect treatment comparisons: Choosing the right tool for the job'
144. Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023. Diabetes Care 2023;46(Suppl. 1):S49–S67.
145. Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes ≥65 and
146. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline
147. The Ile191Val is a partial loss-of-function variant of the TAS1R2 sweet-taste receptor and is associated with reduced glucose excursions in humans
148. Abstract 9295: Ertugliflozin Has Favorable Effects on Kidney Outcomes in Patients With Baseline Evidence of Heart Failure in VERTIS CV
149. Abstract 9341: Hepatic Steatosis Index and Fibrosis-4 Scores in Patients With Type 2 Diabetes - Post Hoc Analyses from VERTIS CV
150. Defining the Proteomic and Phosphoproteomic Landscape of Circulating Extracellular Vesicles in the Diabetes Spectrum
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.